Patents by Inventor Jonathan S. Duke-Cohan

Jonathan S. Duke-Cohan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6933132
    Abstract: The invention features attracting polypeptides and nucleic acids encoding them. The attractin polypeptides are useful for enhancing immune responses.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: August 23, 2005
    Assignee: Dana-Farber Cancer Institute Inc.
    Inventors: Jonathan S. Duke-Cohan, Stuart F. Schlossman
  • Patent number: 6325989
    Abstract: A soluble form of CD26 isolated from human serum is disclosed. The serum form shares similar enzymatic and antigenic properties with the membrane form. However, in several biochemical aspects there are distinct differences. In particular, the soluble serum form has a molecular weight of 175 kDa (in contrast to the 105 kDa molecular weight of the membrane form), and it does not bind Adenosine Deaminase Type-1. Nevertheless, the soluble form expresses functional dipeptidylpeptidase IV activity and retains the ability to costimulate the T lymphocyte response to recall antigen. Although 105 kDa membrane type CD26 may be found in the serum in small amounts, the majority of serum DPPIV activity is provided by a novel peptidase structurally distinct from membrane C26/DPPIV.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 4, 2001
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan S. Duke-Cohan, Chikao Morimoto, Stuart F. Schlossman
  • Patent number: 6265551
    Abstract: A circulating, soluble form of DPPIV/CD26 isolated from human serum is disclosed. The serum form shares similar enzymatic and antigenic properties with the ubiquitous membrane form. However, in several biochemical aspects there are distinct differences. In particular, the circulating serum form has a molecular weight of 175 kDa (in contrast to the 105 kDa molecular weight of the membrane form), and it does not bind Adenosine Deaminase Type-1. Nevertheless, the circulating form expresses functional dipeptidylpeptidase IV activity and retains the ability to costimulate the T lymphocyte response to recall antigen. Circulating DPPIV has been determined to be the soluble form of a 175 kDa DPPIV CD26-related molecule rapidly expressed on the surface of activated T cells, prior to the expression of 105 kDa CD26. Although 105 kDa membrane type CD26 may be found in the serum in small amounts, the majority of serum DPPIV activity is provided by a novel peptidase structurally distinct from 105 kDa CD26/DPPIV.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: July 24, 2001
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan S. Duke-Cohan, Chikao Morimoto, Stuart F. Schlossman